This site is intended for health professionals only

Published on 5 February 2009

Share this story:

Novartis successfully launches $5 billion bond issue


Novartis announced today the successful launch of a major bond market transaction, issuing a two-tranche bond with a total size of $5 billion that has been registered in the US.

The transaction consists of the following tranches:

$2 billion of a 5-year bond with a coupon of 4.125% (issued by the Group’s US entity, Novartis Capital Corp.)

$3 billion of a 10-year bond with a coupon of 5.125% (issued by the Group’s Bermuda unit, Novartis Securities Investment Ltd.)

These bonds are registered with the US Securities and Exchange Commission as part of an automatic shelf registration statement filed by Novartis in 2008. Both tranches are unconditionally guaranteed by Novartis AG, which is incorporated in Switzerland and is the ultimate parent company of the issuing entities.

This transaction further enhances the financial flexibility of Novartis through this access to new sources of funding. Proceeds will be used for general corporate purposes.

To find out more visit:


Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: